PDCD1 and melanoma: Additionally, another clinical study on stage IV melanoma patients treated with nivolumab or ipilimumab (anti-PD-1) reported the overexpression of various circulating exogenous EV-miRNAs, such as miR-155, miR-146a, miR-125b, let-7e, miR-100, miR-125a, miR-99b, and miR-146b, which may predict responses to immunotherapy.